Monday, 17 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,810
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,810 facts checked against source5,217 source documents archived
Work with this data → vianewsagency.com

ONWARD MEDICAL Stock 33.53% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with ONWARD MEDICAL (ONWD.BR) rising 33.53% to €4.50 on Wednesday, after two successive sessions in a row of gains. BEL 20 fell 0.54% to €3,520.52, after four consecutive sessions in a row of losses, on what was a somewhat down trend exchanging session today.

ONWARD MEDICAL's last close was €3.37, 51.79% under its 52-week high of €6.99.

About ONWARD MEDICAL

Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARC-EX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation to treat upper extremity functional deficits with chronic tetraplegia. The company was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Earnings Per Share

As for profitability, ONWARD MEDICAL has a trailing twelve months EPS of €-1.21.

Yearly Top and Bottom Value

ONWARD MEDICAL's stock is valued at €4.50 at 22:33 EST, way below its 52-week high of €6.99 and way above its 52-week low of €3.15.

Volume

Today's last reported volume for ONWARD MEDICAL is 153268 which is 1999.85% above its average volume of 7299.

Volatility

ONWARD MEDICAL's last week, last month's, and last quarter's current intraday variation average was a negative 0.38%, a negative 1.60%, and a positive 2.14%.

ONWARD MEDICAL's highest amplitude of average volatility was 2.05% (last week), 3.24% (last month), and 2.14% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ONWARD MEDICAL's stock is considered to be oversold (<=20).

More news about ONWARD MEDICAL (ONWD.BR).